SCHEMBL1303683

SCHEMBL1303683

NCCC(c1ccccc1)N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.53
KCNA5 P22460 1/20 0.46
HRH1 P35367 1/20 0.46
SLC6A4 P31645 3/20 0.45
ALDH1A1 P00352 4/20 0.44
GRM5 P41594 1/20 0.43
CYP3A4 P08684 2/20 0.42
TSHR P16473 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20746267 0.86 DPP4 (0.64) DPP4KCNA5SLC6A4ALDH1A1GRM5
SCHEMBL856294 0.86 DPP4 (0.64) DPP4KCNA5SLC6A4ALDH1A1GRM5
Hydrochloric Acid SCHEMBL16143658 0.85 DPP4 (0.62) DPP4KCNA5ALDH1A1GRM5CYP3A4
SCHEMBL17086150 0.84 CYP1A2 (0.59) KCNA5HRH1SLC6A4ALDH1A1CYP3A4
SCHEMBL11989937 0.83 OPRM1 (0.58) DPP4KCNA5SLC6A4ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL5755457 0.83 CYP1A2 (0.57) KCNA5HRH1SLC6A4ALDH1A1CYP3A4
SCHEMBL5755490 0.83 CYP1A2 (0.62) KCNA5HRH1SLC6A4ALDH1A1CYP3A4
SCHEMBL5109626 0.82 SLC6A2 (0.47) DPP4SLC6A4ALDH1A1SLC6A2SLC6A3
SCHEMBL23682540 0.82 OPRM1 (0.59) DPP4KCNA5SLC6A4ALDH1A1CYP3A4
SCHEMBL16226508 0.81 OPRM1 (0.53) HRH1SLC6A4CYP2D6SLC6A3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50878-E1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-05 US disclosed
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2020-09-15 US disclosed
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2018-08-23 US disclosed
US-9974791-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-05-22 US disclosed
EP-2860179-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-03-14 EP disclosed
US-20150290208-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2015-10-15 US disclosed
US-9096588-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-08-04 US disclosed
EP-2860179-A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GenKyoTex SA (CH) 2015-04-15 EP disclosed
EP-2344492-B1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2014-10-29 EP disclosed
US-20110269757-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-11-03 US disclosed
EP-2344492-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-20 EP disclosed
WO-2010035221-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
EP-2166010-A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed
EP-1263718-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2001062721-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290208-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB DPP4 1615/4885KCNA5 2355/4885HRH1 1028/4885
US-20110269757-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB DPP4 1615/4885KCNA5 2355/4885HRH1 1028/4885
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB DPP4 1615/4885KCNA5 2355/4885HRH1 1028/4885
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors NOX1, NOX4, CYBB DPP4 1615/4885KCNA5 2355/4885HRH1 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.